Zobrazeno 1 - 10
of 12
pro vyhledávání: '"L T Shimanovskaya"'
Autor:
A E Misyurina, S K Kravchenko, Ya K Mangasarova, A U Magomedova, A M Kovrigina, L T Shimanovskaya, E A Fastova, V A Misyurin, S V Model, D I Chebotarev, I E Kostina, V G Savchenko
Publikováno v:
Терапевтический архив, Vol 91, Iss 4, Pp 107-113 (2019)
Mediastinal gray-zone lymphoma (MGZL, lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma) was declared as a separate entity in WHO classification of Tumors of Haematopoetic and Lymphoid Tissues in
Externí odkaz:
https://doaj.org/article/7cbcda28488c4a5181098ce8cb8dfb7b
Autor:
T. N. Tolstykh, E. N. Misyurina, M. A. Mingalimov, E. A. Baryakh, E. I. Zhelnova, D. E. Gagloeva, S. A. Kardovskaya, T. S. Chudnova, E. N. Zotina, D. D. Ivanova, O. L. Kochneva, K. V. Yatskov, L. T. Shimanovskaya, D. S. Mar’in, A. B. Makeshova, N. G. Chernova, G. A. Dudina, M. A. Granatkin, T. A. Semina, A. V. Misyurin, M. A. Lysenko
Publikováno v:
Онкогематология, Vol 19, Iss 3, Pp 99-111 (2024)
Aim. To evaluate the acute myeloid leukemia (AML) treatment efficacy in adults in Moscow real clinical practice according to the Moscow Cancer Registry data.Materials and methods. We retrospectively collected data from the Moscow Cancer Registry on M
Externí odkaz:
https://doaj.org/article/7f315582fe1a4a3cb87996f49a846926
Autor:
T. S. Chudnova, E. N. Misyurina, E. A. Baryakh, T. N. Tolstykh, L. T. Shimanovskaya, D. E. Gagloeva, E. I. Zhelnova, A. B. Makeshova, K. V. Yatskov, E. N. Zotina, D. D. Ivanova, M. A. Mingalimov, O. L. Kochneva, E. Yu. Grishina, V. N. Yakimets
Publikováno v:
Онкогематология, Vol 19, Iss 3, Pp 206-214 (2024)
Background. Patients with acute lymphoblastic leukemia (ALL) have been the most vulnerable group of patients at risk of severe and extremely severe COVID-19 throughout the coronavirus pandemic. Secondary immunodeficiency due to acute leukemia, as wel
Externí odkaz:
https://doaj.org/article/84e5c35a50cc4b5eade5ae9d63731241
Autor:
V. N. Yakimets, E. N. Misyurina, E. I. Zhelnova, E. A. Baryakh, K. V. Yatskov, A. B. Makeshova, E. A. Karimova, E. N. Zotina, E. Yu. Grishina, D. E. Gagloeva, M. A. Mingalimov, T. N. Tolstykh, T. S. Chudnova, O. L. Kochneva, L. T. Shimanovskaya, Yu. Yu. Polyakov
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 86-90 (2024)
Background. In March 2020, doctors faced the problem of severe COVID-19 coronavirus infection in patients with multiple myeloma. This required a review of issues related to the selection of patients, the development of new preventive and therapeutic
Externí odkaz:
https://doaj.org/article/16908b3edb5e4d8f90a42e770c340559
Autor:
O. L. Kochneva, E. A. Baryakh, E. N. Misyurina, E. I. Zhelnova, K. V. Yatskov, T. S. Chudnova, Yu. Yu. Polyakov, A. B. Makeshova, M. A. Mingalimov, D. D. Ivanova, L. T. Shimanovskaya, E. N. Zotina, T. N. Tolstykh, E. Yu. Grishina, D. E. Gagloeva, V. N. Yakimets, A. I. Koneva, E. A. Karimova
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 64-73 (2024)
Background. At the end of 2019, a new coronavirus infection caused by the SARS-CoV-2 virus was registered. In March 2020, the first cases of COVID-19 were detected in Moscow. Patients with chronic lymphocytic leukemia, characterized by profound immun
Externí odkaz:
https://doaj.org/article/28110400142b4f29a4bdd886c5d5d04d
Autor:
T. S. Chudnova, E. N. Misyurina, E. A. Baryakh, T. N. Tolstykh, L. T. Shimanovskaya, D. E. Gagloeva, E. I. Zhelnova, A. B. Makeshova, K. V. Yatskov, E. N. Zotina, D. D. Ivanova, M. A. Mingalimov, O. L. Kochneva, E. Yu. Grishina, Yu. Yu. Polyakov, V. N. Yakimets
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 45-52 (2024)
Patients with acute leukemia are one of the most vulnerable risk groups for infection with SARS-CoV-2 and severe course of coronavirus infection. During the first 2 years of the pandemic, the mortality rate of patients with acute leukemia was 11-48 %
Externí odkaz:
https://doaj.org/article/562373b3d4a34ce08d461076cd4f6999
Autor:
D. E. Gagloeva, E. N. Misyurina, T. N. Tolstykh, E. A. Baryakh, K. V. Yatskov, E. A. Karimova, A. B. Makeshova, M. A. Mingalimov, T. S. Chudnova, D. D. Ivanova, A. I. Koneva, O. L. Kochneva, E. N. Zotina, E. Yu. Grishina, L. T. Shimanovskaya, V. N. Yakimets, E. I. Zhelnova
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 40-44 (2024)
Background. Acute myeloid leukemia (AML) is a highly aggressive oncological disease of the blood and bone marrow, requiring extremely toxic chemotherapy and massive supportive treatment to achieve stable remission. Currently, there is no work to prov
Externí odkaz:
https://doaj.org/article/5e92b8d878a544aeace85f666ff5d035
Autor:
E. N. Misyurina, E. A. Baryakh, N. F. Frolova, O. N. Kotenko, Z. Yu. Mutovina, S. S. Andreev, T. N. Tolstykh, K. V. Yatskov, E. A. Karimova, A. B. Makeshova, O. A. Rukavitsyn, A. V. Misyurin, Yu. Yu. Polyakov, M. A. Mingalimov, T. S. Chudnova, D. E. Gagloeva, D. D. Ivanova, A. I. Koneva, O. L. Kochneva, E. N. Zotina, E. Yu. Grishina, L. T. Shimanovskaya, V. N. Yakimets, E. I. Zhelnova
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 10-39 (2024)
In December 2019, cases of severe respiratory infection were reported in Wuhan, China. The disease was caused by a new, previously undescribed coronavirus, structurally similar to the then known SARS-CoV virus. The World Health Organization has named
Externí odkaz:
https://doaj.org/article/6c9982b78af94d8e92e3fb3b76bf0c82
Autor:
Yu. Yu. Polyakov, E. A. Baryakh, E. N. Misyurina, E. I. Zhelnova, K. V. Yatskov, A. B. Makeshova, M. A. Mingalimov, T. N. Tolstykh, T. S. Chudnova, D. D. Ivanova, A. I. Koneva, O. L. Kochneva, E. N. Zotina, D. E. Gagloeva, E. Yu. Grishina, L. T. Shimanovskaya, V. N. Yakimets
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 74-85 (2024)
Background. Coronavirus disease (COVID-19), caused by SARS-CoV-2, presents new challenges to hematologists, highlighting the vulnerability of patients with hematological malignancies, in particular with diffuse large B-cell lymphoma (DLBCL). Identifi
Externí odkaz:
https://doaj.org/article/6d577e6096394b05aacb0118ea2f445b
Autor:
E. Yu. Grishina, E. N. Misyurina, E. I. Zhelnova, E. A. Baryakh, K. V. Yatskov, A. B. Makeshova, E. A. Karimova, E. N. Zotina, D. E. Gagloeva, V. N. Yakimets, M. A. Mingalimov, T. N. Tolstykh, Yu. Yu. Polyakov, T. S. Chudnova, O. L. Kochneva, L. T. Shimanovskaya
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 91-95 (2024)
Background. In March 2020, oncohematologists faced the problem of severe COVID-19 coronavirus infection in patients after a high-dose chemotherapy and autologous or allogeneic bone marrow transplantation. This required a review of issues related to t
Externí odkaz:
https://doaj.org/article/ca3560c4cb4a49428d290e92bb3a4258